Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)
17 Luglio 2023 - 10:05PM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of medications to treat severe endocrine, oncology, metabolism and
neurology disorders by modulating the effects of the hormone
cortisol, today announced topline results from a Phase 1b study
evaluating its proprietary cortisol modulator, miricorilant, in
patients with presumed non-alcoholic steatohepatitis (NASH).
The study, which evaluated a range of doses and
dosing schedules of miricorilant, found that patients
who received 100 mg of miricorilant orally every Monday and
Friday for 12 weeks experienced an approximately 30 percent
reduction in liver fat as assessed by MRI-PDFF and showed
improvements in liver enzymes and markers of liver disease. These
patients also experienced improvements in key metabolic and lipid
measures such as HOMA-IR, serum triglycerides and LDL. Importantly,
miricorilant was very well-tolerated. Corcept plans to submit these
results for presentation at a scientific conference. Corcept will
initiate a Phase 2b trial in the fourth quarter to further study
this dosing regimen.
“Miricorilant is highly active in the liver with
a unique mechanism of action and holds great promise for the
treatment of NASH,” said Naim Alkhouri, MD, FAASLD, Chief Medical
Officer of Arizona Liver Health. “The combination of liver fat
reduction, improvement in metabolic and lipid measures and low
adverse event rate is compelling. Miricorilant has the potential to
be a potent solution for the large patient population with
NASH.”
About NASH
Non-alcoholic steatohepatitis (NASH) is an
advanced form of non-alcoholic fatty liver disease (NAFLD) that
afflicts millions of patients and is a leading cause of
liver-related mortality. Cortisol modulation may serve as a
treatment for NASH since cortisol activity at the glucocorticoid
receptor (GR) and mineralocorticoid receptor (MR) has been
implicated in the development and progression of NAFLD. There are
no current medications approved to treat NASH.
About Corcept
Therapeutics
Corcept has discovered a large portfolio of
proprietary compounds that selectively modulate the effects of
cortisol and owns extensive United States and foreign intellectual
property covering both their composition and their use to treat a
variety of serious disorders. Clinical trials are being conducted
with the company’s leading selective cortisol modulators as
potential treatments for patients with serious disorders –
Cushing’s syndrome, ovarian, prostate and adrenal cancer, ALS,
post-traumatic stress disorder and liver disease. Corcept’s drug
Korlym® was the first medication approved by the U.S. Food and Drug
Administration for the treatment of patients with Cushing’s
syndrome.
Forward-Looking
Statements
Statements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those such statements express or imply. These risks
and uncertainties include, but are not limited to, our ability to
operate our business, conduct our clinical trials and achieve our
other goals during the COVID-19 pandemic; risks related to the
development of relacorilant and other product candidates, including
their clinical attributes, regulatory approvals, mandates,
oversight and other requirements; and the scope and protective
power of our intellectual property. These and other risks are set
forth in our SEC filings, which are available at our
website and the SEC’s website.
In this press release, forward-looking
statements include those concerning the timing and substance of our
Phase 1b trial and planned Phase 2b trial in patients with NASH;
and the development of miricorilant as a treatment for NASH,
including its clinical attributes, regulatory approvals, mandates,
oversight, and other requirements. We disclaim any intention or
duty to update forward-looking statements made in this press
release.
CONTACT:Corcept TherapeuticsFor
Investor inquiries: ir@corcept.com For Media
inquiries:CorceptCommunications@corcept.com www.corcept.com
Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Set 2023 a Set 2024